{"id":66234,"date":"2026-05-25T22:55:26","date_gmt":"2026-05-25T14:55:26","guid":{"rendered":"https:\/\/flcube.com\/?p=66234"},"modified":"2026-05-25T22:55:27","modified_gmt":"2026-05-25T14:55:27","slug":"everest-medicines-secures-south-korean-approval-for-velsipity-in-ulcerative-colitis-following-pfizer-arena-legacy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66234","title":{"rendered":"Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Everest Medicines (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>)<\/strong> announced it has received <strong>marketing approval in South Korea<\/strong> for <strong>Velsipity (etrasimod)<\/strong>, a next-generation sphingosine-1-phosphate (S1P) receptor modulator, for the treatment of <strong>adult patients with moderately to severely active ulcerative colitis (UC)<\/strong> who have had an inadequate response, loss of response, or intolerance to conventional therapy or biologics.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-details\" class=\"wp-block-heading\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Everest Medicines (HKG: 1952)<\/td><\/tr><tr><td><strong>Drug Name<\/strong><\/td><td>Velsipity (etrasimod)<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>South Korean Ministry of Food and Drug Safety (MFDS)<\/td><\/tr><tr><td><strong>Approval Status<\/strong><\/td><td>Marketing approval granted<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderately to severely active ulcerative colitis in adults<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Inadequate responders, loss of response, or intolerance to conventional therapy\/biologics<\/td><\/tr><tr><td><strong>Territory Rights<\/strong><\/td><td>Exclusive rights for Greater China and South Korea<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-molecular-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Molecular Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-pharmacological-design\" class=\"wp-block-heading\">Pharmacological Design<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class:<\/strong> Next-generation sphingosine-1-phosphate (S1P) receptor modulator<\/li>\n\n\n\n<li><strong>Receptor Specificity:<\/strong> Binds selectively to S1P receptors 1, 4, and 5<\/li>\n\n\n\n<li><strong>Optimization:<\/strong> Features enhanced pharmacological design compared to first-generation S1P modulators<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Modulates lymphocyte trafficking to reduce inflammatory cell infiltration in the gut<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-differentiation\" class=\"wp-block-heading\">Clinical Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral Administration:<\/strong> Convenient once-daily tablet formulation<\/li>\n\n\n\n<li><strong>Targeted Immunomodulation:<\/strong> Selective receptor binding profile designed to minimize off-target effects<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Optimized to reduce cardiovascular and other systemic side effects associated with earlier S1P modulators<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-corporate-development-history-amp-strategic-rights\" class=\"wp-block-heading\">Corporate Development History &amp; Strategic Rights<\/h2>\n\n\n\n<h3 id=\"h-acquisition-amp-licensing-timeline\" class=\"wp-block-heading\">Acquisition &amp; Licensing Timeline<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Original Developer:<\/strong> Arena Pharmaceuticals developed etrasimod<\/li>\n\n\n\n<li><strong>December 2017:<\/strong> Everest Medicines secured <strong>exclusive rights<\/strong> from Arena for development, manufacturing, and commercialization in <strong>Greater China and South Korea<\/strong><\/li>\n\n\n\n<li><strong>2022:<\/strong> <strong>Pfizer Inc.<\/strong> acquired Arena Pharmaceuticals, inheriting global rights outside Everest&#8217;s licensed territories<\/li>\n\n\n\n<li><strong>Current Status:<\/strong> Everest maintains exclusive commercial rights in its designated Asian markets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This strategic licensing arrangement positions Everest as the sole commercial entity for Velsipity in South Korea and Greater China, creating significant regional market exclusivity.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ulcerative colitis affects approximately <strong>100,000-150,000 patients in South Korea<\/strong>, with a substantial portion failing to respond adequately to existing therapies. The UC treatment landscape includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Conventional therapies:<\/strong> Aminosalicylates, corticosteroids, immunomodulators<\/li>\n\n\n\n<li><strong>Biologics:<\/strong> Anti-TNF agents, integrin inhibitors, JAK inhibitors<\/li>\n\n\n\n<li><strong>Emerging oral options:<\/strong> S1P modulators like Velsipity offer convenient alternatives to injectable biologics<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Velsipity&#8217;s approval provides South Korean physicians with a <strong>novel oral therapeutic option<\/strong> for patients who have exhausted conventional treatments, addressing a critical gap in the treatment algorithm.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The drug competes with other S1P modulators and newer biologic classes, but its <strong>optimized receptor selectivity profile<\/strong> and <strong>once-daily dosing convenience<\/strong> may provide competitive advantages in real-world clinical practice.<\/p>\n\n\n\n<h2 id=\"h-commercial-implications\" class=\"wp-block-heading\">Commercial Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For Everest Medicines, the South Korean approval represents a significant milestone in its strategy to build a pan-Asian specialty pharmaceutical company. The company can leverage its established regulatory expertise and commercial infrastructure across its licensed territories to rapidly deploy Velsipity following local market access negotiations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The approval also validates Everest&#8217;s approach to securing regional rights to innovative global assets, allowing the company to capture value from late-stage development programs without bearing the full cost of global clinical development.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market access, and commercial expectations. Actual results may differ due to risks including pricing negotiations, market competition, reimbursement decisions, and evolving treatment guidelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Everest Medicines (HKG: 1952) announced it has received marketing approval in South Korea for Velsipity&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,126,1164,38],"class_list":["post-66234","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-everest-medicines","tag-hkg-1952","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Everest Medicines (HKG: 1952) announced it has received marketing approval in South Korea for Velsipity (etrasimod), a next-generation sphingosine-1-phosphate (S1P) receptor modulator, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or intolerance to conventional therapy or biologics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66234\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy\" \/>\n<meta property=\"og:description\" content=\"Everest Medicines (HKG: 1952) announced it has received marketing approval in South Korea for Velsipity (etrasimod), a next-generation sphingosine-1-phosphate (S1P) receptor modulator, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or intolerance to conventional therapy or biologics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66234\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-25T14:55:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-25T14:55:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66234#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66234\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy\",\"datePublished\":\"2026-05-25T14:55:26+00:00\",\"dateModified\":\"2026-05-25T14:55:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66234\"},\"wordCount\":530,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Everest Medicines\",\"HKG: 1952\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66234#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66234\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66234\",\"name\":\"Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-25T14:55:26+00:00\",\"dateModified\":\"2026-05-25T14:55:27+00:00\",\"description\":\"Everest Medicines (HKG: 1952) announced it has received marketing approval in South Korea for Velsipity (etrasimod), a next-generation sphingosine-1-phosphate (S1P) receptor modulator, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or intolerance to conventional therapy or biologics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66234#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66234\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66234#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy - Insight, China&#039;s Pharmaceutical Industry","description":"Everest Medicines (HKG: 1952) announced it has received marketing approval in South Korea for Velsipity (etrasimod), a next-generation sphingosine-1-phosphate (S1P) receptor modulator, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or intolerance to conventional therapy or biologics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66234","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy","og_description":"Everest Medicines (HKG: 1952) announced it has received marketing approval in South Korea for Velsipity (etrasimod), a next-generation sphingosine-1-phosphate (S1P) receptor modulator, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or intolerance to conventional therapy or biologics.","og_url":"https:\/\/flcube.com\/?p=66234","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-25T14:55:26+00:00","article_modified_time":"2026-05-25T14:55:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66234#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66234"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy","datePublished":"2026-05-25T14:55:26+00:00","dateModified":"2026-05-25T14:55:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66234"},"wordCount":530,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Everest Medicines","HKG: 1952","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66234#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66234","url":"https:\/\/flcube.com\/?p=66234","name":"Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-25T14:55:26+00:00","dateModified":"2026-05-25T14:55:27+00:00","description":"Everest Medicines (HKG: 1952) announced it has received marketing approval in South Korea for Velsipity (etrasimod), a next-generation sphingosine-1-phosphate (S1P) receptor modulator, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or intolerance to conventional therapy or biologics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66234#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66234"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66234#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66234"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66234\/revisions"}],"predecessor-version":[{"id":66237,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66234\/revisions\/66237"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}